The Tarrytown, New York-based company said it had net income of $8.06 per share. Earnings, adjusted for stock option expense and non-recurring costs, came to $12.07 per share. The results exceeded ...

The Center for Economic Growth will lead the project. The state will offer up to $300,000 for the center to develop a ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

CASE ALLEGATIONS: Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.

SAN FRANCISCO, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Browse through the below gallery to see if you can spot yourself or someone you know!

That knocked Sanofi and Regeneron’s Dupixent and Novo’s Ozempic each down a peg; their TV ad spend totals clocked in at $20.5 million and $18.4 million, respectively. Rounding out December’s ...

Indian banks' loan growth moderated for a sixth straight month in December, central bank data showed on Friday, as the impact ...

Kindly add us to your ad blocker whitelist ... THE positive impact of Regeneron on Limerick's economy continues apace this Thursday with the opening of a 100,000-square foot logistics facility ...

The week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and ...